American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Investing

Here’s why the Bayer share price may rebound after earnings

by admin August 5, 2025
August 5, 2025
Here’s why the Bayer share price may rebound after earnings

Bayer share price pulled back to €27.6 on Tuesday as investors waited for its financial results. It has dropped by 7.3% from its highest level this year, and is about 50% above its lowest level this year. 

Bayer share price technical analysis

The daily chart shows that the Bayer stock price pulled back from the year-to-date high of €29.77 last month to the current €27.60. This chart shows that it has been forming a series of higher highs and higher lows, and is now at a lower point. 

Bayer stock price remains above the 50-day moving average, which has provided it with substantial support since May. The Relative Strength Index (RSI) has moved to the neutral point at 50.

Therefore, the stock will likely resume the uptrend as bulls target the year-to-date high of €29.77. A move above that level will point to more gains, potentially to €30.85, the highest point in September last year. This target price is about 12% above the current level. 

The bullish Bayer share price will be invalidated if it drops below the support at €26.8, which is the 50-day moving average. 

Bayer share price chart | Source: TradingView

Bayer earnings ahead

The most important catalyst for the Bayer stock price will be the upcoming financial results.

Its recent quarterly results will provide more color on its performance. The most recent results showed that its sales were flat to €13.73 billion as its volume and prices retreated. 

Most of the decline happened in the Latin American region, where sales dropped by 10.4% to €1.4 billion. Its EMEA sales also declined by 1.9%, but was partially offset by an increase in the North American and Asia Pacific regions.

READ MORE: Bayer share price is rising: does it have more upside?

The decline, as has happened in the past, was because of its crop science division. This division has deteriorated because of the weaker prices of top commodities like corn and soybeans.

Crop science’s revenue dropped by 4.1% to €7.9 billion. This decline was offset by a 4.4% increase in the pharmaceuticals division, whose revenue jumped by 4.4%. The division was boosted by the volume and price. 

Eylea’s sales rose to €815 million, while the Xarelto’s sales crashed by 31.6% to €633 million. Xarelto’s sales plunged because of the rising competition from genetics medicines. Some of its top growth drugs were Nubeqa, Aspirin, and Kerendia.

Analysts expect this week’s results to show that its revenue was €10.79 billion, with the strong euro having a 4.5% hit on its numbers. The average EBITDA is expected to be €1.8 billion, down from €2.1 billion last year, while its net income will be €67 million, a big improvement from the €34 million loss last year. 

Bayer will also update on the ongoing Roundup litigation. In May, WSJ said that it was seeking a settlement as it explored a Monsanto bankruptcy.

The post Here’s why the Bayer share price may rebound after earnings appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
How tech giants are transforming old European power plants into data centers
next post
Siemens share price analysis ahead of earnings: buy or sell?

Related Posts

USD/JPY forecast: here’s why the Japanese yen is...

October 9, 2025

Sunrun stock price has rebounded: is it a...

June 15, 2025

Brightstar Resources Limited (ASX: BTR) – Trading Halt

July 31, 2024

Signet stock price surges, but a risky pattern...

March 20, 2025

The Zimbabwe ZiG currency is flourishing: here’s why

August 12, 2025

Here’s why SMCI stock price may surge despite...

April 16, 2025

5 Silver Stocks that Pay Dividends (Updated 2024)

May 15, 2024

Crypto crash: why are Bitcoin and altcoins going...

July 25, 2025

Element79 Gold Corp Appoints Warren Levy to Advisory...

May 14, 2024

Cleo Diagnostics

May 21, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Bulgaria plans for continuous oil supply for Lukoil-owned refinery after US sanctions

      October 26, 2025
    • Apple Q4 earnings preview: here’s what to expect

      October 26, 2025
    • France’s offshore wind ambitions stalled by political turmoil

      October 26, 2025
    • Europe bulletin: Zelensky calls for more weapons, Russia warns against EU sanctions

      October 26, 2025
    • US digest: Jeffries endorses Mamdani, Ford’s stock surge, US sanctions Colombian president

      October 26, 2025

    Categories

    • Business (4,373)
    • Investing (3,014)
    • Latest News (2,103)
    • Politics (1,541)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved